Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Insulet to $330 from $375 and keeps an Overweight rating on the shares. The firm notes Insulet reported Q2 sales and EPS that exceeded expectations and raised 2023 sales guidance. Their pipeline remains on track for an eventful 2024, with the launches of O5 outside-U.S., Omnipod Go in the U.S., and continued CGM integration progress.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD: